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The  MARS-5  (Medication  Adherence  Report  Scale)  was  developed  in  English.  The  aim  of this  project
was  to analyse  the  MARS-5I  (© Prof Rob  Horne)  psychometric  properties  and  to  identify  whether  its
Italian  translation  is  suitable  for assessing  medication  adherence  in  Crohn  Disease  (CD)  Italian  patients.
The  MARS  was translated  and linguistically  validated  in  Italian.  The  MARS-5I  was  used  for  evaluating
medication  adherence  in the  SOLE  study,  conducted  in  Italy  on  552  subjects  with  CD.  In order  to  un-
bias  the  questionnaire  results  from  the  effects  of treatment  change  and/or  effectiveness,  the  analyses
were  performed  on the  277  patients  whose  disease  activity  remained  stable,  selected  among  the  371
patients  who  maintained  the  same  treatment  between  two  consecutive  visits.  Internal  consistency  was
high (Cronbach’s  alpha  of 0.86).  Pearson’s  correlation  coefﬁcient  was  0.50  (p <  0.001)  and  0.86  (p  < 0.001-edication adherence
ranslation validation
outliers  removed),  indicating  satisfactory  test-retest.  MARS  5I  scores  were  not  correlated  with  Treatment
Satisfaction  Questionnaire  for  Medication  but a small  and  statistically  signiﬁcant  correlation  was  shown
 medwith physician-evaluatedPlease cite this article in press as: Scribano ML,  et al. Translation and in
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://d
translation  of  the English  MAR
statistically  signiﬁcant  converg
©  2018  Publi
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590-8658/© 2018 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italication  adherence,  indicating  convergent  validity.  MARS-5I,  the  Italianitial validation of the Medication Adherence Report Scale (MARS)
oi.org/10.1016/j.dld.2018.09.026
S,  showed  satisfactory  internal  consistency  and  test-retest,  and  a low  but
ent  validity.  We  conﬁrmed  the utility  of  this  tool  in  patients  with  CD.
shed  by Elsevier  Ltd  on behalf  of Editrice  Gastroenterologica  Italiana  S.r.l.
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. Introduction
Crohn’s disease (CD) is a chronic inﬂammatory condition affect-
ng the gastrointestinal tract, characterized by periods of remission
nd ﬂare-ups [1]. Although reliable epidemiological studies regard-
ng this clinical condition are not available in Italy, CD has been
onsidered to have a nationwide incidence ranging from 2.3 to 5.8
er 100,000 inhabitants [2,3]. More recently a study carried out on
he entire population of the Italian region Lazio reported an inci-
ence of 7.0 per 100.000 inhabitants [4]. These data suggest that
he incidence of CD in Italy may  be higher than previously antic-
pated. Patients suffering from CD are often young, therefore will
ear the burden of the disease for many years, with a major impact
n their daily activities, productivity and quality of life.
The management of CD has been profoundly modiﬁed by the
ntroduction of biologic treatments, in particular by the availability
f Tumour-Necrosis-Factor- (TNF-)  inhibitors. TNF- inhibitors
ave proven highly effective in CD, reducing rates of hospitalization
nd surgery [1,5]. However, despite the availability of such effective
gents, CD treatment remains often suboptimal and ﬂares remain
artly uncontrolled [6].
It has been recently demonstrated that non-adherence to pre-
cribed long-term treatment is a major determinant of treatment
fﬁcacy in inﬂammatory bowel disease (IBD) patients and repre-
ents a common problem in IBD management in clinical practice.
he frequency of non-adherence ranges from 18 to 30% as reported
n several recent international trials [7–10]. In a recent study
f potential triggers for IBD ﬂares, which included non-steroidal
nti-inﬂammatory drug use, antibiotic use, stressful life events,
igarette smoking, infections, travel in the preceding 3 months,
nd medication adherence, only the last one resulted to be signiﬁ-
antly associated with ﬂares [11]. These ﬁndings are incentives to
mprove medication adherence, and to set up tools for measuring
his parameter easily in real life IBD settings.
Since only a single trial regarding treatment adherence in Ital-
an CD population has been published so far [12], we included this
valuation in the SOLE study (Survey on quality Of Life in Crohn’s
atiEnts) protocol.
Among the methods for assessing adherence behaviour, self-
eport measures are the most commonly used in research and
linical care [13]. They represent the most practical tool for mea-
uring adherence, with their easy and ﬂexible administration,
ow-cost, and minimal patient burden. Self-reported measures of
dherence can provide valuable estimates of medication dose-
aking behaviour and information regarding psychosocial factors
elated with adherence (such as reasons for non-adherence and
ttitudes/beliefs toward medicines) [13].
Nevertheless, self-reported measure of adherence can be fre-
uently inaccurate, because patients often fail to recollect whether
hey took the drug or not, and tend to over-report their adherence,
ue to the social desirability of high adherence levels. For these
easons, self-report scales results can suffer from a ceiling effect,
ith the majority of respondent reporting an unrealistic perfect
dherence [13].
Being aware of self-administered adherence measures advan-
ages and disadvantages, we decided to adopt one of these tools
n our protocol, since we considered ease of use and low bur-
en for patients and investigators outweighing their drawbacks.
mong the available tools we chose the 5 items Medication Adher-
nce Report Scale (MARS-5 - ©Professor Rob Horne), a widely used
imple self-administered questionnaire [14].
The MARS-5 is aimed to collect information regarding patient’sPlease cite this article in press as: Scribano ML,  et al. Translation and in
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://d
evel of adherence to the prescribed pharmacological therapy. It is
 generic tool, which can be administered regardless of the disease
nd the prescribed drug. It has been validated so far in different
linical settings, namely statin therapy [15], rheumatoid arthritis PRESS
er Disease xxx (2018) xxx–xxx
[16], asthma [17], psychosis [18], and has been used for assessing
adherence in many clinical studies worldwide [19–37].
The MARS-5 consists of 5 items describing non-adherent
behaviours (“I forget to take the medicine / I alter the dose of
medicine / I stop taking the medicine for a while / I decided to
miss out a dose / I take less than instructed”): patients are asked
to evaluate how often they adopt each behaviour with a 5 point
scale, ranging from “always” to “never” (1–5 points). The scale total
score ranges from 5 (lowest adherence) to 25 points (maximal
adherence).
The MARS-5 was  originally developed in English [14], and has
been translated in German, Swedish, and Portuguese [38–40]. Due
to the lack of an Italian version of the MARS-5 (MARS-5I © Prof. Rob
Horne), the scale was translated before SOLE study start and the
Italian translation performed linguistic validation. The aim of this
project was to analyse the MARS-5I psychometric properties and
to identify whether its Italian translation is a suitable instrument
for assessing medication adherence in CD Italian patients, in order
to be able to have a fast and simple tool to quantify the patients’
compliance.
2. Materials and methods
2.1. The MARS-5I linguistic validation
The MARS was  originally translated into Italian by two indepen-
dent professional translators. The translations were then discussed
during a consensus conference, which both the translators attended
along with three supervising gastroenterologists. During the con-
ference the two translations were evaluated; the one considered
more clear and accurate was selected and consequently amended
according to suggestions made by the physicians.
The ﬁnal Italian translation was  then back translated into
English by a mother tongue professional translator; the back trans-
lation was  approved by the MARS originator, Professor Rob Horne,
and then tested in a group of 15 patients. The patients were
asked to answer the MARS-5I items and to report any difﬁculty
in understanding them. Following this comprehension evaluation,
no further amendments to the MARS-5I were required.
2.2. The SOLE Study
The validated MARS-5I was then used for evaluating medication
adherence in the SOLE study, a large multicentre survey, conducted
in Italy in 38 referral centres, on adult (≥18 years) subjects with a
diagnosis of active CD, prospectively recruited over a 12-month
observation period between September 2011 and November 2013
(n = 552), with visits scheduled at baseline, 3, 6 and 12 months.
Patient’s disease activity in SOLE study was measured with
Harvey-Bradshaw Index (HBI), a ﬁve questions, simpliﬁed version
of the Crohn’s Disease Activity Index [41]. HBI index total score
ranges from 0 to >16, with scores <5 indicating remission, and
scores >16 indicating severe disease. In SOLE study HBI score at
enrolment had to be ≥8 (moderate-to-severe disease).
Primary objective of the SOLE study was to evaluate the qual-
ity of life (QoL) evolution during the study and its relationship
with the patients’ working capability and productivity. Secondary
objectives were to determine the relationship between QoL and dis-
ease activity, patient satisfaction and compliance with treatment,
to assess the structural and organizational variables of the involved
gastroenterology centres, to estimate the cost of illness of CD in a
12 months period, and to assess its relationship with QoL.itial validation of the Medication Adherence Report Scale (MARS)
oi.org/10.1016/j.dld.2018.09.026
2.3. The MARS-5I evaluation
Here we present some additional analyses of SOLE study results
conducted to evaluate the MARS-5I.
 IN PRESSG ModelY
nd Liver Disease xxx (2018) xxx–xxx 3
a
w
u
t
t
o
o
r
p
s
s
r
a
a
p
t
r
2
5
s
t
w
i
V
2
b
t
t
s
t
r
b
u
B
d
d
a
o
o
p
t
c
o
2
d
s
S
t
r
i
h
t
c
m
t
Table 1
Characteristics of the study sample.
MARS validation
samplea (n = 277)
Total populationb
(n = 552)
N % N %
Gender
Male 130 46.93 271 49.09
Female 147 53.07 281 50.91
Age class
18–25 47 16.97 72 13.04
26–35 71 25.63 139 25.18
36–45 60 21.66 127 23.01
46–55 64 23.10 130 23.55
>55  35 12.64 84 15.22
Living with partner
Yes 145 52.35 307 55.62
No  132 47.65 245 44.38
Education
Primary school 16 5.78 35 6.34
Junior high school 66 23.83 146 26.45
High school 154 55.70 287 51.99
University 41 14.80 84 15.21
Employment
Employed 158 57.04 300 54.35
Unemployed 119 42.96 252 45.66
Treatment
Not  biologic drugs 95 34.30 263 51.27
Biologic drugs 182 65.70 260 47.10
Comorbidities
Yes  184 66.43 352 63.77
Concomitant diseases
Yes 118 42.60 239 43.30ARTICLEDLD-3884; No. of Pages 8
M.L. Scribano et al. / Digestive a
Since the SOLE study was an epidemiological study, conducted
s per clinical routine, with no obligations to provide the patients
ith any particular treatment at any time point, the whole pop-
lation (552 pts) consisted of patients with all combinations of
reatments and start dates. In order to eliminate the bias due to
he effects of a treatment change and/or the relevant effectiveness
n the questionnaire, we conducted these analyses on a subgroup
f 277 patients, whose disease activity (measured with HBI index)
emained quite stable (HBI score ±4), selected among the 371
atients who maintained the same treatment between two con-
ecutive visits (visit 2 and visit 3, at 3 and 6 months from study
tart respectively). This is particularly important for the test-retest
eliability that is a measure of how much the results obtained with
 scale are consistent across time. It is measured by administering
 test twice, at two different time points, supposing the measured
henomenon has not changed. MARS-5I was subjected to statis-
ical analysis in order to evaluate internal consistency, test-retest
eliability, and convergent validity.
.3.1. Internal consistency
When different items are used to form a scale, such in the MARS-
I, they need to have internal consistency. In other words, they
hould be correlated with one another, all measuring the same
hing (adherence). To measure the MARS-5I internal consistency
e used the Cronbach’s alpha coefﬁcient, which ranges from 0 (the
tems are independent) to 1 (the items are perfectly correlated).
alues of 0.7-0.8 are generally regarded as satisfactory [42].
.3.2. Test-retest reliability
Test-retest reliability is measured by the correlation coefﬁcient
etween the results collected at two different time points.
For evaluating the MARS-5I test-retest reliability, we compared
he results of SOLE study visits 2 and 3 (3 months interval between
he two visits, always on the subpopulation remaining on the
ame treatment and with a modest HBI change) and calculated
he Pearson’s correlation coefﬁcient. Pearson’s coefﬁcient values
anges from −1 to 1, with 1 indicating a perfect correspondence
etween the two tests, and 0 indicating no correspondence. We
sed a threshold of 0.8 to consider the MARS-5I reliable.
The MARS-5I reproducibility was also evaluated using
land–Altman plot [43]. This plot is used for comparing two
ifferent measures of the same nature; it consists in a dispersion
iagram with the difference between the two measures on Y-axis,
nd the reference value obtained calculating the arithmetic mean
f the two values on X-axis. The horizontal lines represent the mean
f differences, and the mean of differences ±2xSD. Bland–Altman
lot consists of the investigator’s opinion: if the mean variation in
he conﬁdence interval is not relevant, the two methods can be
onsidered interchangeable. It is not based on critical values, but
n expert opinion.
.3.3. Validity
In order to evaluate the MARS-5I convergent validity we con-
ucted two different analyses.
In the ﬁrst one we assumed that results obtained with this
cale correlate with those obtained with another scale used in
OLE study: the Treatment Satisfaction Questionnaire for Medica-
ion (TSQM, providing a global treatment satisfaction score). We
elied on the hypothesis that a high level of treatment satisfaction
s directly correlated with a high level of treatment adherence. The
ypothesis is widely recognised and conﬁrmed by trials in many
herapeutic settings [44–47]. For assessing the hypothesis that aPlease cite this article in press as: Scribano ML,  et al. Translation and in
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://d
orrelation exists between MARS and TSQM we calculated Spear-
an’s rho correlation.
In the second analysis we used Spearman’s rho for assessing
he correlation between MARS-5I results and a physician eval-a At the ﬁrst considered visit (visit 2).
b At the ﬁnal analysis.
uated medication adherence score. In fact, during SOLE study
investigators were required to evaluate their patients’ medication
adherence with a 5 point scale, ranging from 1 to 5 (never to always
adherent). For this analysis MARS-5I scores were categorized in 5
classes (“never adherent: scores 5-9”; “seldom adherent: 10–14”;
“sometimes adherent: 15–19”; “often adherent: 20–24”; “always
adherent: 25”).
2.3.4. Inﬂuence of patient characteristics on MARS-5I scores
We analysed all the factors potentially related with treatment
adherence with a logistic regression model. A binomial variable
based on MARS-5I scores was created:
• MARS score < 25: lower treatment adherence
• MARS score = 25: perfect treatment adherence
We considered as independent variables: gender, age, educa-
tion, marital status, employment status, treatment, comorbidities
and concomitant diseases. Estimates were corrected for the “centre
effect”, due to the possible correlation between subjects enrolled
by the same centre.
3. Results
Among the 277 patients evaluated the majority were women
(53%), and about 26% was between 26 and 35 years old. 52% of
patients lived with a partner, 56% had a high school diploma,itial validation of the Medication Adherence Report Scale (MARS)
oi.org/10.1016/j.dld.2018.09.026
57% was  employed, 66% was  treated with biologic drugs, 66% had
comorbidities, and 43% concomitant diseases (Table 1).
The mean disease activity score (HBI) at the ﬁrst considered
visit (visit 2) was 4.9 (SD 2.6; median 5.0; range 0–12; interquartile
ARTICLE IN PRESSG ModelYDLD-3884; No. of Pages 8
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Table 2
Disease activity and MARS-5I score of the study sample at visit 2.
N Mean SD Minimum Maximum 25th Pctl Median 75th Pctl
HBI index 277 4.90 2.61 0.00a 12.00 3.00 5.00 7.00
MARS-5I 277 23.73 2.41 5.00 25.00 23.00 25.00 25.0
Pctl: percentile. SD: Standard Deviation. HBI: Harvey–Bradshaw Index. MARS: Medication Adherence Report Scale. MARS-5I: Italian version of the MARS.
a 11 patients with disease activity = 0 at the ﬁrst considered visit (visit 2).
Table 3
Chronbach’s alpha results for internal consistency evaluation.
Cronbach’s alpha value (N = 277)
Complete MARS-5I 0.86
Excluding single items of MARS-5I
Item 1 0.85
Item 2 0.83
Item 3 0.84
Item 4 0.82
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Fig. 1. A) Scatter plot of MARS-5I values at visit 2 and 3. Line represents the ﬁtted
regression between MARS values. Circles have diameter dimensions proportional
to  the frequency of paired values; B) Bland Altman plot of MARS scores differences
and means for test-retest reliability evaluation. Circles’ diameter is proportional to
frequencies of patients presenting the same differences and same means.
MARS: Medication Adherence Report Scale.
Table 4
Correlation between MARS-5I scores and TSQM scores or physician evaluated adher-
ence scores for validity analysis, calculated with Spearman’s rho.
N Spearman’s rho P value
TSQM
General satisfaction 276 0.05 0.378
Adverse events 277 0.03 0.650
Efﬁcacy 276 0.03 0.586
Convenience 276 0.04 0.479Item 5 0.82
ARS: Medication Adherence Report Scale. MARS-5I: Italian version of the MARS.
ange: 3.0–7.0); the mean MARS-5I score was 23.7 (SD 2.4; median
5.0; range 5–25; interquartile range 23–25) (Table 2).
.1. Internal consistency
Internal consistency was satisfactory, with a Cronbach’s alpha of
.86. This value is very good, and falls within the German validation
tudy interval (0.67-0.90) [38] (Table 3). We  also reported alpha
alues calculated after excluding single MARS-5I items. Items 4 (“I
ecide to miss out a dose”) and 5 (“I take less than instructed”)
eemed to have a little higher weight, i.e. when excluded, alpha
alue was smaller.
.2. Test-retest reliability
Retest evaluation included 275 patients and the calculated Pear-
on’s correlation coefﬁcient was 0.50 (p < 0.001), quite a suboptimal
esult. Fig. 1A shows a graphical representation of MARS results
airs obtained at visits 2 and 3 for each patient in the sample group.
he majority of values was  equal to 25, but there were also outlier
alues, with a really high difference between visit 2 and 3, that
ould be due to a real change in adherence.
Bland Altman Plot (Fig. 1B) shows that about 95% of differences
ell within −5 and 5; despite the mean value was close to zero
which indicate a good reproducibility), variation remained high
±5). Excluding values which fell outside the ±2 SD interval, the
btained correlation coefﬁcient was 0.86 (p < 0.001).
.3. Validity
The ﬁrst analysis for validity evaluation, in which TSQM ques-
ionnaire was used as comparator (total score and subscores), is
eported in Table 4. The correlation values showed the absence
f relation between the two questionnaires. The second analysis,
n which we assessed the correlation between the physician eval-
ated medication adherence score and MARS-5I score, showed a
eak level of correlation (rho = 0.15, p = 0.014), although statisti-
ally signiﬁcant (Table 4).
.4. Incidence of patients characteristics on reported adherencePlease cite this article in press as: Scribano ML,  et al. Translation and initial validation of the Medication Adherence Report Scale (MARS)
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://doi.org/10.1016/j.dld.2018.09.026
Table 5 shows results of the logistic model we used to evaluate
he patients characteristics related with perfect adherence (“per-
ect adherence predictors”). Patient characteristics which showed
igniﬁcant correlation with adherence were increasing age (OR
Adherence evaluated by physicians 277 0.15 0.014
MARS: Medication Adherence Report Scale. MARS-5I: Italian version of the MARS.
TSQM: Treatment Satisfaction Questionnaire for Medication.
ARTICLE IN PRESSG ModelYDLD-3884; No. of Pages 8
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Table  5
Patient characteristics potentially related to perfect treatment adherence (MARS-5I = 25).
Subgroup analysis (n = 277) SOLE total population (n = 466)
OR 95%IC p value OR 95%IC p value
Gender
Male 1.00 1.00
Female 1.11 0.67 1.82 0.681 1.11 0.79 1.55 0.536
Class  age
18–25 1.00 1.00
26–35  1.47 0.68 3.19 0.322 1.59 0.76 3.34 0.209
36–45  1.54 0.68 3.51 0.291 1.85 0.96 3.56 0.066
46–55  2.25 1.08 4.70 0.032 1.81 0.93 3.52 0.081
>55  3.38 1.59 7.16 0.002 2.65 1.34 5.23 0.006
Living with partner
Yes 1.74 1.08 2.8 0.024 1.60 1.11 2.30 0.013
No  1.00 1.00
Education
Primary school 2.14 0.75 6.16 0.152 2.66 1.24 5.70 0.014
Junior high school 1.16 0.67 2.04 0.572 0.87 0.52 1.45 0.575
High  school 1.00 1.00
University 2.35 0.98 5.65 0.055 1.59 0.92 2.75 0.093
Employment
Employed 1.00 1.00
Not  employed 1.12 0.66 1.88 0.669 0.35 0.62 1.47 0.815
Treatment
Not  biologic drugs 1.00 1.00
Biologic drugs 3.73 2.02 6.88 <0.001 3.42 2.23 5.27 <0.001
Speciﬁc treatment
Not biologic drugs 1.00 1.00
Inﬂiximab 2.24 1.32 7.95 0.012 2.89 1.52 5.49 0.002
Adalimumab 4.17 2.24 7.77 <0.001 3.85 2.34 3.66 <0.001
Comorbidities
No  1.00 1.00
Yes  1.77 0.87 3.61 0.114 1.65 0.97 2.83 0.065
Concomitant diseases
No 1.00 1.00
Yes  1.30 0.76 2.23 0.325 1.26 0.63 1.73 0.156
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tesults of a logistic regression model based on a binomial variable derived from M
reatment adherence. Independent variables: gender, age, education, marital status
orrected for the “center effect”. MARS: Medication Adherence Report Scale. MARS-
or patients >55 years old 3.38, 95% CI 1.59–7.16 p = .002), living
ith a partner (OR: 1.74, 95% CI1.08-2.08, p = 0.024), and treat-
ent with biologic drugs both considering the whole drug category
OR: 3.73, 95% CI 2.02–6.88, p < 0.001), and the two  different
ctive ingredients [OR for inﬂiximab and adalimumab 2.24 (95% CI
.32–7.95,p = 0.012) and 4.17 (95% CI 2.24–7.77, p < 0.001) respec-
ively]. These factors were also found to be signiﬁcant predictors
or perfect adherence in the total population.
. Discussion
In our analysis the Italian version of the widely used MARS scale
howed a satisfactory internal consistency, and the level of test-
etest reliability was good when excluding outlier patients (out
f ±2SD). As for validity evaluation, a low correlation was  shown
etween MARS-5I and physician evaluated medication adherence
cores, probably due to a different perception of the patient’s adher-
nce from the physician point of view, while we  failed to show any
orrelation between MARS-5I and TSQM results.
It is important to recognise that our study was not origi-
ally designed for evaluating the MARS-5I scale. Consequently our
nalyses present several important limitations and are not a com-Please cite this article in press as: Scribano ML,  et al. Translation and in
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://d
rehensive evaluation of validity and test-retest reliability. For
nstance, the selection of our sample group (n = 277), based only on
tability of disease activity, could be biased. In fact, compared with
he total population of SOLE study, in our sample there were several5I scores: MARS score <25, lower treatment adherence; MARS score = 25, perfect
oyment status, treatment, comorbidities and concomitant diseases. Estimates were
lian version of the MARS.
discrepancies in medication adherence related characteristics. The
sub-group used for the MARS-5I evaluation comprised more males,
more patients living without a partner, with a high level of educa-
tion, employed, on biologic drugs, than the full SOLE participants,
although the statistical signiﬁcance of these differences has not
been evaluated. Moreover, in the subgroup analysed, MARS scores
did not show a uniform distribution, but were generally above 20,
indicating generally high reports of adherence.
The study design did not afford a true test of assessment of
test-retest reliability as the duration between assessments was too
long. It is reasonable to assume that, for some participants, levels
of adherence may  have changed signiﬁcantly during this period. In
this case, low correlation between MARS scores at 1 vs 3 months
could be a reﬂection of changing adherence rates rather than low
test-retest reliability. The fact that test-reliability ﬁgures were sig-
niﬁcantly higher after removal of outliers supports this explanation.
Based on this data we  consider the MARS-5I to have adequate test-
retest reliability.
In the German and Swedish MARS linguistic validation stud-
ies, the intervals between tests for the test-retest evaluation were
shorter than in our analysis, namely 3-4 weeks and ≥7 days respec-
tively [38,39]. In the Portuguese study the interval was  evenitial validation of the Medication Adherence Report Scale (MARS)
oi.org/10.1016/j.dld.2018.09.026
shorter, consisting in only 2 days [40]. Our interval was  much
longer, far from the ideal time span of 2–4 weeks; this could have
resulted in objective major changes in patients characteristics inﬂu-
encing adherence, such as general health status and anxiety level.
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oreover, although the disease activity remained quite stable
etween the two visits (since this was the main criteria we used
o select this subgroup of patients), 3 months is a long enough time
pan for the typical CD seasonal variations [48] to be observed, with
 possible effect on adherence.
The two validity analysis we conducted gave contradictory
esults. The one based on MARS-5I correlation with TSQM failed to
rove MARS-5I convergent validity. On the contrary, the one based
n MARS-5I correlation with the physician evaluated medication
dherence score showed a low value, nevertheless with statistical
igniﬁcance. The results of our ﬁrst analysis could be due to the
act that MARS and TSQM scales assess very different constructs:
he ﬁrst one assesses a reported behaviour (reported adherence),
hile the second one assesses a perception (perception of treat-
ent satisfaction). This discrepancy is likely to be the reason of
ur results. In fact, using two scales measuring the same construct
medication adherence) such as MARS-5I and the physician evalu-
ted medication adherence score, we obtained a fair better result.
ur Spearman’s Rho value (0.15, p < 0.014) was similar to the one
btained in the German MARS evaluation [38] (0.26, p < 0.01), in
hich a Satisfaction with Information about Medicine Scale (SIMS-
) was used as a comparator for MARS-5I in the convergent validity
nalysis.
Our exploratory data examining association between
ichotomized MARS and other variables do not constitute a
ormal test of validity. Yet they are interesting, because they
ighlight individual characteristics signiﬁcantly associated with
etter reported adherence, allowing us to provide more tar-
eted interventions with the aim of supporting adherence in our
atients.
In previously published studies parameters associated with
reater adherence to medical therapy in IBD patients were age,
ollow-up by a gastroenterologist, and immunosuppressant use
8,9]. Lower rates of treatment adherence were associated with
mployment status, high scores on the Obstacles to Medication
se Scale, short disease duration, high education level, dissatis-
action with the patient–doctor relationship, mood disorders, and
ge younger than 40 [7–10,49]. Moreover, patients’ personal beliefs
bout the IBD and its treatment are important, potentially modi-
able, determinants of both adherence and nonadherence [50,51].
 large study of UK patients with IBD found that nonadherence
as related to implicit evaluations of maintenance treatment, with
onadherence related to doubts about personal need for mainte-
ance treatment and concerns about potential harm associated
ith regular use over the long-term [50]. These ﬁndings suggest
hat interventions to improve adherence should take account of
he perceptions (e.g. medication necessity beliefs and concerns)
s well as practicalities (e.g. capability and resources) inﬂuencing
otivations and ability to adhere to treatment [52]. Interventions
o support adherence should therefore ensure that doubts about
ersonal need for the medication are not based on misconceptions
bout illness and treatment, and that the patients concerns about
reatment have been elicited and addressed [53].
Our analysis suggests increasing age may  be associated with
mproved medical adherence, and highlights for the ﬁrst time
hat treatment with biologic drugs is signiﬁcantly associated with
igher reported adherence in CD. This is consistent with a previous
eport in psoriasis, where self-reported adherence to biologics was
ound to be signiﬁcantly greater than that of other drug classes [54];
he reasons were supposed to be a higher motivation due to the
everity of the disease and/or to the training patients are supplied
n the use of biologics. This is true both for the whole drug class andPlease cite this article in press as: Scribano ML,  et al. Translation and in
in Italian patients with Crohn’s Disease. Dig Liver Dis (2018), https://d
or the two different active ingredients considered in our analysis
inﬂiximab and adalimumab). In CD, adalimumab adherence has
een reported to be higher than inﬂiximab in a systematic review
55]. The observed differences in the odds of being fully adherent PRESS
er Disease xxx (2018) xxx–xxx
between inﬂiximab and adalimumab showed in our study could be
related more to the type of administration than to the type of drug
itself. In fact, physicians might be more prone to administer adali-
mumab  to adherent patients and inﬂiximab, due to its intravenous
administration, to less adherent patients [55]. Adalimumab, on the
contrary, can be administered subcutaneously by the patient, after
an initial training.
Our analysis represents the ﬁrst attempt to validate an Ital-
ian translation of MARS scale using data of a wide, multicentre,
observational study. We  have conﬁrmed the utility of this tool in
medication adherence evaluation in patients with CD,  and for sim-
ply ﬁnding those at higher risk of reduced adherence, requiring an
intervention in order to improve their therapeutic outcomes.
In our study MARS-5I, the Italian translation of the original
English MARS scale, showed a satisfactory internal consistency and
a low but statistically signiﬁcant convergent validity based on the
correlation with a physician evaluated medication adherence score.
The low level of MARS-5I test-retest reliability emerged in this
analysis is probably due to the long time passed between the two
questionnaire administrations. Further studies, with shorter inter-
vals between tests, will be needed to clarify this point.
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